Spotlight: Dr. Girish Kulkarni 

Dr. Girish Kulkarni is the recipient of a $300,000 Movember Clinician Scientist award for 2012. He is taking a unique look at prostate cancer treatment by studying personalized medicine at Princess Margaret Hospital. 

Here’s a closer look at Dr. Kulkarni’s work.

There are some risks associated with prostate biopsy, including pain, problems with urination or infection. Dr. Kulkarni’s research will develop models to identify when prostate biopsy could be delayed, such as with patients most likely to have a negative biopsy or a very low-risk prostate cancer where treatment would not be recommended. Patients and clinicians will be able to use these models for personalized clinical decision-making.

We talked with Dr. Kulkarni about his views on prostate cancer research:

What does the funding for the Clinician Scientist award mean to you?
This is an extremely important award for me. It will help protect my time so I can devote all of my energies to prostate cancer research. It will provide support to answer important questions in prostate cancer research. Finally, it will help launch my research career and establish my trajectory as a prostate cancer scientist. 
How does research funding help scientists in Canada?
Research funding is integral to advancements in prostate cancer research. With government research funding cutbacks in the current economic climate, funds by organizations such as PCC will help scientists across the country continue to perform groundbreaking research that will ultimately decrease the burden prostate cancer places on patients.
What are your views on the future of prostate cancer research in Canada?
I think prostate cancer research is going to take off in Canada over the next 5 years. With the success of fundraising campaigns spearheaded by PCC, support in all domains of prostate cancer research will be possible and will ultimately benefit patients in Canada and abroad.

Inscrivez-vous à nos nouvelles

* obligatoire

Contenu en vedette
Rocco Rossi conclut un mandat réussi de cinq ans à titre de président et chef de la direction de Cancer de la Prostate Canada

7 septembre 2017 - TORONTO (ONTARIO) - C’est avec beaucoup d’émotion que le président et chef de la direction de longue date de Cancer de la Prostate Canada (CPC), Rocco Rossi, a officiellement annoncé aujourd’hui qu’il quittera ses fonctions à la barre de l’organisation le 31 décembre 2017.

La Fondation Movember et Cancer de la Prostate Canada font équipe pour transformer la recherche en résultats

26 juillet 2017 – TORONTO (ONTARIO) – Fidèles à leur longue tradition de partenariat pour le financement de recherches de grande qualité sur le cancer de la prostate au Canada, Cancer de la Prostate Canada (CPC) et la Fondation Movember ont annoncé aujourd’hui deux nouveaux projets qui offrent un potentiel très réel de changer concrètement le cours des choses pour les hommes atteints de formes virulentes du cancer de la prostate.

Cancer de la prostate nouvelles